<article article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23579211</article-id><article-id pub-id-type="pmc">3668468</article-id><article-id pub-id-type="pii">bjc2013145</article-id><article-id pub-id-type="doi">10.1038/bjc.2013.145</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Patient-reported outcomes for axitinib <italic>vs</italic> sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial</article-title><alt-title alt-title-type="running">Patient-reported outcomes in second-line mRCC</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cella</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rini</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bhattacharyya</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Tarazi</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Rosbrook</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Motzer</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine</institution>, 633 N. St, Clair – 19th Floor Chicago, IL 60611, <country>USA</country></aff><aff id="aff2"><label>2</label><institution>Department of Medicine, Institut Gustave Roussy</institution>, 39 rue Camille Desmoulins, Villejuif Cedex 94805, <country>France</country></aff><aff id="aff3"><label>3</label><institution>Solid Tumor Oncology, The Cleveland Clinic Taussig Cancer Institute</institution>, 9500 Euclid Avenue, Cleveland, OH 44195, <country>USA</country></aff><aff id="aff4"><label>4</label><institution>Global Outcomes Research, Pfizer Inc</institution>, 235 East 42nd Street, New York, NY 10017, <country>USA</country></aff><aff id="aff5"><label>5</label><institution>Pfizer Oncology</institution>, 10646 Science Center Drive, La Jolla, San Diego, CA 92121, <country>USA</country></aff><aff id="aff6"><label>6</label><institution>Department of Medicine, Memorial Sloan-Kettering Cancer Center</institution>, 1275 York Avenue, New York, NY 10065, <country>USA</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>d-cella@northwestern.edu</email></corresp></author-notes><pub-date pub-type="ppub"><day>30</day><month>04</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>11</day><month>04</month><year>2013</year></pub-date><volume>108</volume><issue>8</issue><fpage>1571</fpage><lpage>1578</lpage><history><date date-type="received"><day>21</day><month>11</month><year>2012</year></date><date date-type="rev-recd"><day>01</day><month>03</month><year>2013</year></date><date date-type="accepted"><day>07</day><month>03</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2013 Cancer Research UK</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><license-p>From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/</license-p></license></permissions><abstract><sec><title><offsets xml_i="4845" xml_f="4856" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="4867" xml_f="4923" txt_i="23" txt_f="79">Axitinib demonstrated greater progression-free survival </offsets><italic><offsets xml_i="4931" xml_f="4933" txt_i="79" txt_f="81">vs</offsets></italic><offsets xml_i="4942" xml_f="5285" txt_i="81" txt_f="424"> sorafenib in a phase III study of previously treated patients with metastatic renal cell carcinoma. Here, we report patient-reported kidney-specific symptoms and health status, measured by the Functional Assessment of Cancer Therapy (FACT) Kidney Cancer Symptom Index (FKSI) and the European Quality of Life self-report questionnaire (EQ-5D).</offsets></p></sec><sec><title><offsets xml_i="5307" xml_f="5315" txt_i="426" txt_f="434">Methods:</offsets></title><p><offsets xml_i="5326" xml_f="5676" txt_i="435" txt_f="785">In all, 723 patients received axitinib (starting dose 5 mg twice daily (b.i.d.)) or sorafenib (400 mg b.i.d.). The FKSI-15, including the disease-related symptoms (FKSI-DRS) subscale, was administered on day 1 before dosing, every 4 weeks and at end of treatment (EOT)/withdrawal. Statistical methods included a mixed-effects repeated-measures model.</offsets></p></sec><sec><title><offsets xml_i="5698" xml_f="5706" txt_i="787" txt_f="795">Results:</offsets></title><p><offsets xml_i="5717" xml_f="6063" txt_i="796" txt_f="1142">At baseline, patients in both arms had relatively high mean FSKI-15 and FKSI-DRS scores, comparable to the general US population. Subsequent on-treatment overall mean scores were similar between axitinib and sorafenib, and there was no substantial decline during treatment. Scores substantially worsened at EOT, mainly due to disease progression.</offsets></p></sec><sec><title><offsets xml_i="6085" xml_f="6096" txt_i="1144" txt_f="1155">Conclusion:</offsets></title><p><offsets xml_i="6107" xml_f="6407" txt_i="1156" txt_f="1456">Patient-reported outcomes were comparable for second-line axitinib and sorafenib and were maintained at relatively high levels while on treatment, but worsened at EOT. As duration of treatment was longer with axitinib than sorafenib, time to worsening of symptoms can be delayed longer with axitinib.</offsets></p></sec></abstract><kwd-group><kwd>axitinib</kwd><kwd>patient reported outcomes</kwd><kwd>quality of life</kwd><kwd>renal cell carcinoma</kwd><kwd>sorafenib</kwd></kwd-group></article-meta></front><body><p><offsets xml_i="6615" xml_f="6828" txt_i="1465" txt_f="1678">Patients with metastatic renal cell carcinoma (mRCC) typically experience cancer-related symptoms and impaired health-related quality of life (HRQoL) that significantly impact daily functioning and limit therapy (</offsets><xref ref-type="bibr" rid="bib14"><offsets xml_i="6862" xml_f="6870" txt_i="1678" txt_f="1686">Harding </offsets><italic><offsets xml_i="6878" xml_f="6883" txt_i="1686" txt_f="1691">et al</offsets></italic><offsets xml_i="6892" xml_f="6898" txt_i="1691" txt_f="1697">, 2007</offsets></xref><offsets xml_i="6905" xml_f="6907" txt_i="1697" txt_f="1699">; </offsets><xref ref-type="bibr" rid="bib13"><offsets xml_i="6941" xml_f="6947" txt_i="1699" txt_f="1705">Gupta </offsets><italic><offsets xml_i="6955" xml_f="6960" txt_i="1705" txt_f="1710">et al</offsets></italic><offsets xml_i="6969" xml_f="6975" txt_i="1710" txt_f="1716">, 2008</offsets></xref><offsets xml_i="6982" xml_f="6984" txt_i="1716" txt_f="1718">; </offsets><xref ref-type="bibr" rid="bib5"><offsets xml_i="7017" xml_f="7028" txt_i="1718" txt_f="1729">Cella, 2009</offsets></xref><offsets xml_i="7035" xml_f="7139" txt_i="1729" txt_f="1833">). Furthermore, the impact of symptoms and treatment-related toxicity on HRQoL is often underestimated (</offsets><xref ref-type="bibr" rid="bib14"><offsets xml_i="7173" xml_f="7181" txt_i="1833" txt_f="1841">Harding </offsets><italic><offsets xml_i="7189" xml_f="7194" txt_i="1841" txt_f="1846">et al</offsets></italic><offsets xml_i="7203" xml_f="7209" txt_i="1846" txt_f="1852">, 2007</offsets></xref><offsets xml_i="7216" xml_f="7218" txt_i="1852" txt_f="1854">; </offsets><xref ref-type="bibr" rid="bib13"><offsets xml_i="7252" xml_f="7258" txt_i="1854" txt_f="1860">Gupta </offsets><italic><offsets xml_i="7266" xml_f="7271" txt_i="1860" txt_f="1865">et al</offsets></italic><offsets xml_i="7280" xml_f="7286" txt_i="1865" txt_f="1871">, 2008</offsets></xref><offsets xml_i="7293" xml_f="7295" txt_i="1871" txt_f="1873">; </offsets><xref ref-type="bibr" rid="bib5"><offsets xml_i="7328" xml_f="7339" txt_i="1873" txt_f="1884">Cella, 2009</offsets></xref><offsets xml_i="7346" xml_f="7428" txt_i="1884" txt_f="1966">). Measurement of HRQoL outcomes provides information on the effect of treatment (</offsets><xref ref-type="bibr" rid="bib35"><offsets xml_i="7462" xml_f="7469" txt_i="1966" txt_f="1973">Wagner </offsets><italic><offsets xml_i="7477" xml_f="7482" txt_i="1973" txt_f="1978">et al</offsets></italic><offsets xml_i="7491" xml_f="7497" txt_i="1978" txt_f="1984">, 2007</offsets></xref><offsets xml_i="7504" xml_f="7751" txt_i="1984" txt_f="2231">) and assists the evaluation of the trade-off between extended progression-free survival (PFS) and treatment toxicity that, given disease progression rates following first-line treatment failure, is particularly relevant for second-line therapies.</offsets></p><p><offsets xml_i="7758" xml_f="7796" txt_i="2232" txt_f="2270">Metastatic RCC is difficult to treat (</offsets><xref ref-type="bibr" rid="bib20"><offsets xml_i="7830" xml_f="7834" txt_i="2270" txt_f="2274">Lam </offsets><italic><offsets xml_i="7842" xml_f="7847" txt_i="2274" txt_f="2279">et al</offsets></italic><offsets xml_i="7856" xml_f="7862" txt_i="2279" txt_f="2285">, 2004</offsets></xref><offsets xml_i="7869" xml_f="7935" txt_i="2285" txt_f="2348">); without effective treatment patients often die in &lt;2 years (</offsets><xref ref-type="bibr" rid="bib21"><offsets xml_i="7969" xml_f="7991" txt_i="2348" txt_f="2370">Linehan and Zbar, 2004</offsets></xref><offsets xml_i="7998" xml_f="8129" txt_i="2370" txt_f="2501">). The disease is often resistant to chemotherapy, but targeted treatments, including tyrosine kinase inhibitors (TKIs; sunitinib (</offsets><xref ref-type="bibr" rid="bib25"><offsets xml_i="8163" xml_f="8170" txt_i="2501" txt_f="2508">Motzer </offsets><italic><offsets xml_i="8178" xml_f="8183" txt_i="2508" txt_f="2513">et al</offsets></italic><offsets xml_i="8192" xml_f="8198" txt_i="2513" txt_f="2519">, 2007</offsets></xref><offsets xml_i="8205" xml_f="8219" txt_i="2519" txt_f="2533">), sorafenib (</offsets><xref ref-type="bibr" rid="bib9"><offsets xml_i="8252" xml_f="8261" txt_i="2533" txt_f="2542">Escudier </offsets><italic><offsets xml_i="8269" xml_f="8274" txt_i="2542" txt_f="2547">et al</offsets></italic><offsets xml_i="8283" xml_f="8290" txt_i="2547" txt_f="2554">, 2007a</offsets></xref><offsets xml_i="8297" xml_f="8299" txt_i="2554" txt_f="2556">, </offsets><xref ref-type="bibr" rid="bib10"><offsets xml_i="8333" xml_f="8337" txt_i="2556" txt_f="2560">2009</offsets></xref><offsets xml_i="8344" xml_f="8358" txt_i="2560" txt_f="2574">), pazopanib (</offsets><xref ref-type="bibr" rid="bib31"><offsets xml_i="8392" xml_f="8402" txt_i="2574" txt_f="2584">Sternberg </offsets><italic><offsets xml_i="8410" xml_f="8415" txt_i="2584" txt_f="2589">et al</offsets></italic><offsets xml_i="8424" xml_f="8430" txt_i="2589" txt_f="2595">, 2010</offsets></xref><offsets xml_i="8437" xml_f="8520" txt_i="2595" txt_f="2678">)), the vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (</offsets><xref ref-type="bibr" rid="bib11"><offsets xml_i="8554" xml_f="8563" txt_i="2678" txt_f="2687">Escudier </offsets><italic><offsets xml_i="8571" xml_f="8576" txt_i="2687" txt_f="2692">et al</offsets></italic><offsets xml_i="8585" xml_f="8592" txt_i="2692" txt_f="2699">, 2007b</offsets></xref><offsets xml_i="8599" xml_f="8692" txt_i="2699" txt_f="2792">) and temsirolimus and everolimus (inhibitors of the mammalian target of rapamycin pathway) (</offsets><xref ref-type="bibr" rid="bib18"><offsets xml_i="8726" xml_f="8732" txt_i="2792" txt_f="2798">Hudes </offsets><italic><offsets xml_i="8740" xml_f="8745" txt_i="2798" txt_f="2803">et al</offsets></italic><offsets xml_i="8754" xml_f="8760" txt_i="2803" txt_f="2809">, 2007</offsets></xref><offsets xml_i="8767" xml_f="8769" txt_i="2809" txt_f="2811">; </offsets><xref ref-type="bibr" rid="bib24"><offsets xml_i="8803" xml_f="8810" txt_i="2811" txt_f="2818">Motzer </offsets><italic><offsets xml_i="8818" xml_f="8823" txt_i="2818" txt_f="2823">et al</offsets></italic><offsets xml_i="8832" xml_f="8838" txt_i="2823" txt_f="2829">, 2008</offsets></xref><offsets xml_i="8845" xml_f="8847" txt_i="2829" txt_f="2831">, </offsets><xref ref-type="bibr" rid="bib23"><offsets xml_i="8881" xml_f="8885" txt_i="2831" txt_f="2835">2010</offsets></xref><offsets xml_i="8892" xml_f="8948" txt_i="2835" txt_f="2891">), have demonstrated clinical benefit in these patients.</offsets></p><p><offsets xml_i="8955" xml_f="9057" txt_i="2892" txt_f="2994">Axitinib is a potent and selective second-generation inhibitor of VEGF receptors (VEGFR)-1, 2, and 3 (</offsets><xref ref-type="bibr" rid="bib17"><offsets xml_i="9091" xml_f="9099" txt_i="2994" txt_f="3002">Hu-Lowe </offsets><italic><offsets xml_i="9107" xml_f="9112" txt_i="3002" txt_f="3007">et al</offsets></italic><offsets xml_i="9121" xml_f="9127" txt_i="3007" txt_f="3013">, 2008</offsets></xref><offsets xml_i="9134" xml_f="9240" txt_i="3013" txt_f="3119">). Phase II studies demonstrated clinical activity in patients with advanced RCC refractory to cytokines (</offsets><xref ref-type="bibr" rid="bib28"><offsets xml_i="9274" xml_f="9279" txt_i="3119" txt_f="3124">Rixe </offsets><italic><offsets xml_i="9287" xml_f="9292" txt_i="3124" txt_f="3129">et al</offsets></italic><offsets xml_i="9301" xml_f="9307" txt_i="3129" txt_f="3135">, 2007</offsets></xref><offsets xml_i="9314" xml_f="9330" txt_i="3135" txt_f="3151">) or sorafenib (</offsets><xref ref-type="bibr" rid="bib27"><offsets xml_i="9364" xml_f="9369" txt_i="3151" txt_f="3156">Rini </offsets><italic><offsets xml_i="9377" xml_f="9382" txt_i="3156" txt_f="3161">et al</offsets></italic><offsets xml_i="9391" xml_f="9397" txt_i="3161" txt_f="3167">, 2009</offsets></xref><offsets xml_i="9404" xml_f="9649" txt_i="3167" txt_f="3412">). In a randomised phase III clinical trial (AXIS) that compared the efficacy and safety of axitinib with sorafenib in patients with advanced RCC with disease progression after first-line systemic therapy, median PFS for axitinib was 6.7 months </offsets><italic><offsets xml_i="9657" xml_f="9659" txt_i="3412" txt_f="3414">vs</offsets></italic><offsets xml_i="9668" xml_f="9720" txt_i="3414" txt_f="3466"> 4.7 months for sorafenib (hazard ratio (HR)=0.665; </offsets><italic><offsets xml_i="9728" xml_f="9729" txt_i="3466" txt_f="3467">P</offsets></italic><offsets xml_i="9738" xml_f="9751" txt_i="3467" txt_f="3477">&lt;0.0001) (</offsets><xref ref-type="bibr" rid="bib26"><offsets xml_i="9785" xml_f="9790" txt_i="3477" txt_f="3482">Rini </offsets><italic><offsets xml_i="9798" xml_f="9803" txt_i="3482" txt_f="3487">et al</offsets></italic><offsets xml_i="9812" xml_f="9818" txt_i="3487" txt_f="3493">, 2011</offsets></xref><offsets xml_i="9825" xml_f="10075" txt_i="3493" txt_f="3743">). Results for the composite end point of time-to-treatment deterioration (TTD; defined as a decrease in quality of life (worsening of Functional Assessment of Cancer Therapy (FACT) Kidney Symptom Index-15 (FKSI-15) score), progression or death; see </offsets><xref ref-type="bibr" rid="bib26"><offsets xml_i="10109" xml_f="10114" txt_i="3743" txt_f="3748">Rini </offsets><italic><offsets xml_i="10122" xml_f="10127" txt_i="3748" txt_f="3753">et al</offsets></italic><offsets xml_i="10136" xml_f="10143" txt_i="3753" txt_f="3760"> (2011)</offsets></xref><offsets xml_i="10150" xml_f="10155" txt_i="3760" txt_f="3765"> and </offsets><xref ref-type="bibr" rid="bib1"><offsets xml_i="10188" xml_f="10193" txt_i="3765" txt_f="3770">Amir </offsets><italic><offsets xml_i="10201" xml_f="10206" txt_i="3770" txt_f="3775">et al</offsets></italic><offsets xml_i="10215" xml_f="10222" txt_i="3775" txt_f="3782"> (2012)</offsets></xref><offsets xml_i="10229" xml_f="10314" txt_i="3782" txt_f="3867"> for further details) were also reported, but an overall assessment of HRQoL was not.</offsets></p><p><offsets xml_i="10321" xml_f="10367" txt_i="3868" txt_f="3914">This report summarises the effect of axitinib </offsets><italic><offsets xml_i="10375" xml_f="10377" txt_i="3914" txt_f="3916">vs</offsets></italic><offsets xml_i="10386" xml_f="10535" txt_i="3916" txt_f="4065"> sorafenib on patient-reported kidney cancer-specific symptoms/functioning and health status, which were secondary end points of the phase III study.</offsets></p><sec sec-type="materials|methods"><title><offsets xml_i="10580" xml_f="10601" txt_i="4066" txt_f="4087">Materials and methods</offsets></title><sec><title><offsets xml_i="10621" xml_f="10646" txt_i="4088" txt_f="4113">Study design and patients</offsets></title><p><offsets xml_i="10657" xml_f="10927" txt_i="4114" txt_f="4384">The pre-specified patient-reported outcome end point analyses were derived from a prospective, open-label, randomised phase III clinical trial in patients with advanced RCC after failure of one first-line systemic regimen, details of which have been reported elsewhere (</offsets><xref ref-type="bibr" rid="bib26"><offsets xml_i="10961" xml_f="10966" txt_i="4384" txt_f="4389">Rini </offsets><italic><offsets xml_i="10974" xml_f="10979" txt_i="4389" txt_f="4394">et al</offsets></italic><offsets xml_i="10988" xml_f="10994" txt_i="4394" txt_f="4400">, 2011</offsets></xref><offsets xml_i="11001" xml_f="11190" txt_i="4400" txt_f="4589">). Briefly, eligible patients were stratified according to Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1) and prior therapy (sunitinib-, bevacizumab/interferon (IFN)-</offsets><italic><offsets xml_i="11198" xml_f="11199" txt_i="4589" txt_f="4590">α</offsets></italic><offsets xml_i="11208" xml_f="11500" txt_i="4590" txt_f="4882">-, temsirolimus-, or cytokine-based regimens) and randomised (1 : 1) to axitinib or sorafenib. Inclusion criteria included age ⩾18 years; histologically or cytologically confirmed RCC with a clear cell component; measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) (</offsets><xref ref-type="bibr" rid="bib32"><offsets xml_i="11534" xml_f="11543" txt_i="4882" txt_f="4891">Therasse </offsets><italic><offsets xml_i="11551" xml_f="11556" txt_i="4891" txt_f="4896">et al</offsets></italic><offsets xml_i="11565" xml_f="11571" txt_i="4896" txt_f="4902">, 2000</offsets></xref><offsets xml_i="11578" xml_f="11668" txt_i="4902" txt_f="4992">); and ⩾2 weeks since the end of prior systemic treatment or ⩾4 weeks for bevacizumab/IFN-</offsets><italic><offsets xml_i="11676" xml_f="11677" txt_i="4992" txt_f="4993">α</offsets></italic><offsets xml_i="11686" xml_f="12000" txt_i="4993" txt_f="5307"> treatment. Patients were excluded if they had central nervous system metastasis; uncontrolled hypertension (blood pressure (BP) ⩾140/90 mm Hg); clinically significant cardiovascular disease or events within 12 months before study drug administration; or deep vein thrombosis or pulmonary embolism within 6 months.</offsets></p><p><offsets xml_i="12007" xml_f="12314" txt_i="5308" txt_f="5615">The trial was approved by an institutional review board or ethics committee at each centre and complied with Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws. All patients provided written informed consent. The trial is registered on ClinicalTrials.gov, identifier NCT00678392.</offsets></p></sec><sec><title><offsets xml_i="12336" xml_f="12354" txt_i="5617" txt_f="5635">Treatment regimens</offsets></title><p><offsets xml_i="12365" xml_f="13092" txt_i="5636" txt_f="6357">Axitinib was administered orally at a starting dose of 5 mg twice daily (b.i.d.). Patients who tolerated this dose with no significant treatment-related grade &gt;2 adverse reactions for a 2-week period had their dose increased to 7 mg b.i.d., unless BP was &gt;150/90 mm Hg or they were receiving antihypertensive medication. Using the same criteria, patients who tolerated 7 mg b.i.d. had their dose increased to a maximum of 10 mg b.i.d. Axitinib dose reductions were allowed for management of toxicity. The sorafenib starting dose was 400 mg b.i.d., which could be reduced to 400 mg once daily or 400 mg every other day to manage toxicity. Patients were treated until disease progression (per RECIST criteria, version 1.0; </offsets><xref ref-type="bibr" rid="bib32"><offsets xml_i="13126" xml_f="13135" txt_i="6357" txt_f="6366">Therasse </offsets><italic><offsets xml_i="13143" xml_f="13148" txt_i="6366" txt_f="6371">et al</offsets></italic><offsets xml_i="13157" xml_f="13163" txt_i="6371" txt_f="6377">, 2000</offsets></xref><offsets xml_i="13170" xml_f="13243" txt_i="6377" txt_f="6450">), occurrence of unacceptable toxicity or death or withdrawal of consent.</offsets></p></sec><sec><title><offsets xml_i="13265" xml_f="13298" txt_i="6452" txt_f="6485">Patient-reported outcome measures</offsets></title><p><offsets xml_i="13309" xml_f="13368" txt_i="6486" txt_f="6545">Patient-reported outcomes were assessed using the FKSI-15 (</offsets><xref ref-type="bibr" rid="bib7"><offsets xml_i="13401" xml_f="13407" txt_i="6545" txt_f="6551">Cella </offsets><italic><offsets xml_i="13415" xml_f="13420" txt_i="6551" txt_f="6556">et al</offsets></italic><offsets xml_i="13429" xml_f="13435" txt_i="6556" txt_f="6562">, 2006</offsets></xref><offsets xml_i="13442" xml_f="13469" txt_i="6562" txt_f="6589">) and the EuroQoL (EQ-5D) (</offsets><xref ref-type="bibr" rid="bib19"><offsets xml_i="13503" xml_f="13513" txt_i="6589" txt_f="6599">Kind, 1996</offsets></xref><offsets xml_i="13520" xml_f="14509" txt_i="6599" txt_f="7588">), and were completed at screening, after every 4 weeks of therapy, at end of study treatment, and at follow-up (28 days after end of therapy). End of treatment (EOT) and follow-up data were collected at different cycles, reflecting the different times that patients went off treatment. To avoid potential bias, questionnaires were completed before patients discussed their disease status with health-care professionals. The FKSI-15 includes 15 items: lack of energy, bothered by side effects, pain, weight loss, bone pain, fatigue, enjoyment of life, shortness of breath, worry condition may worsen, appetite, coughing, bothered by fevers, ability to work, haematuria, and sleeping well. In this trial, two scores–the FKSI-15 total score and the FKSI-Disease-Related Symptoms (FKSI-DRS) score–were derived. The FKSI-DRS is a 9-item subscale of FKSI-15 that includes lack of energy, pain, weight loss, bone pain, fatigue, shortness of breath, coughing, bothered by fevers, and haematuria (</offsets><xref ref-type="bibr" rid="bib6"><offsets xml_i="14542" xml_f="14548" txt_i="7588" txt_f="7594">Cella </offsets><italic><offsets xml_i="14556" xml_f="14561" txt_i="7594" txt_f="7599">et al</offsets></italic><offsets xml_i="14570" xml_f="14576" txt_i="7599" txt_f="7605">, 2007</offsets></xref><offsets xml_i="14583" xml_f="15350" txt_i="7605" txt_f="8369">). Each question was answered on a 5-point Likert-type scale ranging from 0 to 4 (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). The FKSI-15 score (range 0–60) is the sum of the 15 individual items, and the FKSI-DRS score (range 0–36) is the sum of its 9 individual item scores. For some questions, answers were the item scores; for other questions, answers were reverse coded such that higher scores corresponded to better HRQoL and fewer symptoms. If answers to individual questions were missing, then scores were calculated as the pro-rated sum of the non-missing items (provided &gt;50% of the questions, e.g., at least 8 of 15 for FKSI-15, were answered). Both the FKSI-15 and FKSI-DRS have been validated in patients with kidney cancer (</offsets><xref ref-type="bibr" rid="bib7"><offsets xml_i="15383" xml_f="15389" txt_i="8369" txt_f="8375">Cella </offsets><italic><offsets xml_i="15397" xml_f="15402" txt_i="8375" txt_f="8380">et al</offsets></italic><offsets xml_i="15411" xml_f="15417" txt_i="8380" txt_f="8386">, 2006</offsets></xref><offsets xml_i="15424" xml_f="15426" txt_i="8386" txt_f="8388">, </offsets><xref ref-type="bibr" rid="bib6"><offsets xml_i="15459" xml_f="15463" txt_i="8388" txt_f="8392">2007</offsets></xref><offsets xml_i="15470" xml_f="15564" txt_i="8392" txt_f="8486">). An important difference was estimated to be 3–5 points for the FKSI-15 scale (range 0–60) (</offsets><xref ref-type="bibr" rid="bib7"><offsets xml_i="15597" xml_f="15603" txt_i="8486" txt_f="8492">Cella </offsets><italic><offsets xml_i="15611" xml_f="15616" txt_i="8492" txt_f="8497">et al</offsets></italic><offsets xml_i="15625" xml_f="15631" txt_i="8497" txt_f="8503">, 2006</offsets></xref><offsets xml_i="15638" xml_f="15695" txt_i="8503" txt_f="8560">) and 2–3 points for the FKSI-DRS (range 0–36) subscale (</offsets><xref ref-type="bibr" rid="bib6"><offsets xml_i="15728" xml_f="15734" txt_i="8560" txt_f="8566">Cella </offsets><italic><offsets xml_i="15742" xml_f="15747" txt_i="8566" txt_f="8571">et al</offsets></italic><offsets xml_i="15756" xml_f="15762" txt_i="8571" txt_f="8577">, 2007</offsets></xref><offsets xml_i="15769" xml_f="15771" txt_i="8577" txt_f="8579">).</offsets></p><p><offsets xml_i="15778" xml_f="16042" txt_i="8580" txt_f="8844">The EQ-5D is a preference-based generic health status measure and comprises two components, an index score with five items (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a visual analogue scale score for overall health state (</offsets><xref ref-type="bibr" rid="bib19"><offsets xml_i="16076" xml_f="16086" txt_i="8844" txt_f="8854">Kind, 1996</offsets></xref><offsets xml_i="16093" xml_f="16193" txt_i="8854" txt_f="8954">). For this study, we used the index scoring algorithm derived from a UK general population sample (</offsets><xref ref-type="bibr" rid="bib19"><offsets xml_i="16227" xml_f="16237" txt_i="8954" txt_f="8964">Kind, 1996</offsets></xref><offsets xml_i="16244" xml_f="16246" txt_i="8964" txt_f="8966">).</offsets></p></sec><sec><title><offsets xml_i="16268" xml_f="16288" txt_i="8968" txt_f="8988">Statistical analysis</offsets></title><p><offsets xml_i="16299" xml_f="16717" txt_i="8989" txt_f="9407">All analyses were performed on the intent-to-treat population. Descriptive statistics were used to summarise demographic and clinical characteristics and patient-reported outcome scores by treatment arm. Comparisons of post-treatment scores were performed using a repeated-measures mixed-effects model, including terms for treatment, time and treatment-by-time, with baseline as covariate and time assumed continuous (</offsets><xref ref-type="bibr" rid="bib30"><offsets xml_i="16751" xml_f="16775" txt_i="9407" txt_f="9431">Singer and Willett, 2003</offsets></xref><offsets xml_i="16782" xml_f="16784" txt_i="9431" txt_f="9433">; </offsets><xref ref-type="bibr" rid="bib15"><offsets xml_i="16818" xml_f="16843" txt_i="9433" txt_f="9458">Hedeker and Gibbons, 2006</offsets></xref><offsets xml_i="16850" xml_f="17032" txt_i="9458" txt_f="9640">). This model permits multiple observations at different time points, but assumes missing values are missing at random. To account for the possibility of data missing not at random (</offsets><xref ref-type="bibr" rid="bib29"><offsets xml_i="17066" xml_f="17077" txt_i="9640" txt_f="9651">Rubin, 1976</offsets></xref><offsets xml_i="17084" xml_f="17086" txt_i="9651" txt_f="9653">; </offsets><xref ref-type="bibr" rid="bib34"><offsets xml_i="17120" xml_f="17127" txt_i="9653" txt_f="9660">Troxel </offsets><italic><offsets xml_i="17135" xml_f="17140" txt_i="9660" txt_f="9665">et al</offsets></italic><offsets xml_i="17149" xml_f="17155" txt_i="9665" txt_f="9671">, 1998</offsets></xref><offsets xml_i="17162" xml_f="17329" txt_i="9671" txt_f="9838">) (e.g., variation in missing values due to treatment), pattern mixture models were explored as a sensitivity analysis. All available data were used in these analyses.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="17376" xml_f="17383" txt_i="9841" txt_f="9848">Results</offsets></title><sec><title><offsets xml_i="17403" xml_f="17427" txt_i="9849" txt_f="9873">Baseline characteristics</offsets></title><p><offsets xml_i="17438" xml_f="17486" txt_i="9874" txt_f="9922">In all, 723 patients were assigned to axitinib (</offsets><italic><offsets xml_i="17494" xml_f="17495" txt_i="9922" txt_f="9923">n</offsets></italic><offsets xml_i="17504" xml_f="17524" txt_i="9923" txt_f="9943">=361) or sorafenib (</offsets><italic><offsets xml_i="17532" xml_f="17533" txt_i="9943" txt_f="9944">n</offsets></italic><offsets xml_i="17542" xml_f="17616" txt_i="9944" txt_f="10018">=362) treatment. Baseline characteristics have been described previously (</offsets><xref ref-type="bibr" rid="bib26"><offsets xml_i="17650" xml_f="17655" txt_i="10018" txt_f="10023">Rini </offsets><italic><offsets xml_i="17663" xml_f="17668" txt_i="10023" txt_f="10028">et al</offsets></italic><offsets xml_i="17677" xml_f="17683" txt_i="10028" txt_f="10034">, 2011</offsets></xref><offsets xml_i="17690" xml_f="17830" txt_i="10034" txt_f="10174">). Baseline demographic and clinical characteristics, as well as baseline FKSI-15 and FKSI-DRS scores, were similar between treatment arms (</offsets><xref rid="tbl1" ref-type="table"><offsets xml_i="17864" xml_f="17871" txt_i="10174" txt_f="10181">Table 1</offsets></xref><offsets xml_i="17878" xml_f="17881" txt_i="10181" txt_f="10184">) (</offsets><xref ref-type="bibr" rid="bib22"><offsets xml_i="17915" xml_f="17922" txt_i="10184" txt_f="10191">Motzer </offsets><italic><offsets xml_i="17930" xml_f="17935" txt_i="10191" txt_f="10196">et al</offsets></italic><offsets xml_i="17944" xml_f="17950" txt_i="10196" txt_f="10202">, 2004</offsets></xref><offsets xml_i="17957" xml_f="17959" txt_i="10202" txt_f="10204">; </offsets><xref ref-type="bibr" rid="bib16"><offsets xml_i="17993" xml_f="17998" txt_i="10204" txt_f="10209">Heng </offsets><italic><offsets xml_i="18006" xml_f="18011" txt_i="10209" txt_f="10214">et al</offsets></italic><offsets xml_i="18020" xml_f="18026" txt_i="10214" txt_f="10220">, 2009</offsets></xref><offsets xml_i="18033" xml_f="18035" txt_i="10220" txt_f="10222">).</offsets></p></sec><sec><title><offsets xml_i="18057" xml_f="18075" txt_i="10224" txt_f="10242">Dose modifications</offsets></title><p><offsets xml_i="18086" xml_f="18390" txt_i="10243" txt_f="10547">During treatment, 199 (55.4%) and 220 (62.0%) patients had at least one dose interruption due to adverse events in the axitinib and sorafenib arms, respectively, and 95 (26.5%) and 73 (20.6%) patients had at least one dose reduction due to adverse events in the axitinib and sorafenib arms, respectively.</offsets></p></sec><sec><title><offsets xml_i="18412" xml_f="18453" txt_i="10549" txt_f="10590">Patient-reported outcome completion rates</offsets></title><p><offsets xml_i="18464" xml_f="18717" txt_i="10591" txt_f="10841">The patient-reported outcome completion rate was &gt;85% at baseline, and for the majority of the study 90% or more eligible patients contributed to the patient-reported analyses at each cycle. The number of eligible patients was higher in the axitinib </offsets><italic><offsets xml_i="18725" xml_f="18727" txt_i="10841" txt_f="10843">vs</offsets></italic><offsets xml_i="18736" xml_f="19187" txt_i="10843" txt_f="11294"> sorafenib arm due to varying dropout rates resulting from differential rates of disease progression (e.g., by cycle 8, 52.1% of patients in the axitinib arm were eligible compared with 40.1% in the sorafenib arm). At EOT, in both treatment arms, the majority of patients who had stopped treatment had done so because of disease progression, with adverse events accounting for 10.0% and 12.9% of cases in the axitinib and sorafenib arms, respectively.</offsets></p></sec><sec><title><offsets xml_i="19209" xml_f="19225" txt_i="11296" txt_f="11312">FKSI assessments</offsets></title><p><offsets xml_i="19236" xml_f="19339" txt_i="11313" txt_f="11416">Observed FKSI-15 means and corresponding sample sizes for the axitinib and sorafenib arms are shown in </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="19371" xml_f="19379" txt_i="11416" txt_f="11424">Figure 1</offsets></xref><offsets xml_i="19386" xml_f="19493" txt_i="11424" txt_f="11531">. Mean values for axitinib and sorafenib were almost identical at baseline (43.20 and 43.34, respectively; </offsets><xref rid="tbl1" ref-type="table"><offsets xml_i="19527" xml_f="19534" txt_i="11531" txt_f="11538">Table 1</offsets></xref><offsets xml_i="19541" xml_f="20179" txt_i="11538" txt_f="12176">) and remained similar throughout the study. The FKSI-15 scores for both treatments worsened (dropped) at EOT (axitinib, 38.33; sorafenib, 38.46). End of treatment was, in the majority of cases, triggered by disease progression. Mean values for 28-day follow-up were 41.92 and 40.03 in the axitinib and sorafenib arms, respectively, which were somewhat higher than the respective values at EOT; however, compliance at this time point had dropped to ∼40% in both treatment arms. To examine if there was a responder bias, all end-of-treatment data from patients in both treatment arms were combined and divided into two groups; those with (</offsets><italic><offsets xml_i="20187" xml_f="20188" txt_i="12176" txt_f="12177">n</offsets></italic><offsets xml_i="20197" xml_f="20222" txt_i="12177" txt_f="12202">=169) and those without (</offsets><italic><offsets xml_i="20230" xml_f="20231" txt_i="12202" txt_f="12203">n</offsets></italic><offsets xml_i="20240" xml_f="20379" txt_i="12203" txt_f="12342">=194) follow-up (day 28) data. Patients with follow-up data had a significantly higher mean FKSI-15 score at EOT than those without (40.15 </offsets><italic><offsets xml_i="20387" xml_f="20389" txt_i="12342" txt_f="12344">vs</offsets></italic><offsets xml_i="20398" xml_f="20438" txt_i="12344" txt_f="12384"> 37.01, respectively; difference, 3.14; </offsets><italic><offsets xml_i="20446" xml_f="20447" txt_i="12384" txt_f="12385">P</offsets></italic><offsets xml_i="20456" xml_f="20717" txt_i="12385" txt_f="12646">=0.0009). Furthermore, the mean FKSI-15 score at EOT for patients with follow-up was almost identical to their mean score at follow-up (40.15 and 40.81, respectively), suggesting that healthier patients were the ones contributing to the 28-day follow-up scores.</offsets></p><p><offsets xml_i="20724" xml_f="20955" txt_i="12647" txt_f="12878">No statistically significant differences between axitinib and sorafenib were observed using a repeated measures mixed-effects model. Post-treatment least squares means were 42.21 and 41.86 for axitinib and sorafenib, respectively (</offsets><italic><offsets xml_i="20963" xml_f="20964" txt_i="12878" txt_f="12879">P</offsets></italic><offsets xml_i="20973" xml_f="20982" txt_i="12879" txt_f="12888">=0.4833; </offsets><xref rid="tbl2" ref-type="table"><offsets xml_i="21016" xml_f="21023" txt_i="12888" txt_f="12895">Table 2</offsets></xref><offsets xml_i="21030" xml_f="21098" txt_i="12895" txt_f="12963">). There was no significant interaction between treatment and time (</offsets><italic><offsets xml_i="21106" xml_f="21107" txt_i="12963" txt_f="12964">P</offsets></italic><offsets xml_i="21116" xml_f="21205" txt_i="12964" txt_f="13053">=0.3943), indicating no difference in the course of the treatment effect over the cycles.</offsets></p><p><offsets xml_i="21212" xml_f="21366" txt_i="13054" txt_f="13208">The mixed-effects analysis was also performed for each of the individual items of the FKSI-15. No significant treatment effect was observed for any item (</offsets><xref rid="tbl3" ref-type="table"><offsets xml_i="21400" xml_f="21407" txt_i="13208" txt_f="13215">Table 3</offsets></xref><offsets xml_i="21414" xml_f="22212" txt_i="13215" txt_f="14010">). Owing to the differential dropout rates between the two treatment arms, a pattern-mixture analysis was performed as a sensitivity analysis. Two patterns were defined: completers (patients completing &gt;168 days (6 cycles) of treatment) and dropouts (those completing 168 or fewer days of treatment). A threshold of six cycles was chosen, as this was the last cycle in which over 50% of patients in both treatment arms remained in the study. Results were similar to those of the standard mixed-effects model. A pattern-mixture analysis was also performed based on three patterns where the thresholds were study days 84 and 196 (i.e., end of cycles 3 and 8 upon completion of radiologic determinations of tumour progression). Again, there was no significant difference between the treatment arms.</offsets></p><p><offsets xml_i="22219" xml_f="23164" txt_i="14011" txt_f="14956">There was no significant treatment difference in FKSI-15 scores for patients who had received prior sunitinib or patients who received prior cytokine therapy based on the mixed-effects analysis. Baseline scores were similar for both treatments in both subgroups (prior sunitinib–axitinib arm 42.68; sorafenib arm 42.97; prior cytokines–axitinib arm 44.04; sorafenib arm 44.54). Scores in both subgroups remained similar throughout treatment and worsened at EOT (prior sunitinib–axitinib arm 36.86; sorafenib arm 37.15; prior cytokines–axitinib arm 40.30; sorafenib arm 40.32). Analysis by MSKCC risk subgroup (favourable, intermediate, poor) also showed no significant treatment difference in any of the MSKCC subgroups. The difference in the risk groups was reflected in the baseline scores (favourable–axitinib arm 46.89; sorafenib arm 47.47; intermediate–axitinib arm 43.20; sorafenib arm 43.23; poor–axitinib arm 40.44; sorafenib arm 39.83).</offsets></p></sec><sec><title><offsets xml_i="23186" xml_f="23206" txt_i="14958" txt_f="14978">FKSI-DRS assessments</offsets></title><p><offsets xml_i="23217" xml_f="23369" txt_i="14979" txt_f="15131">The mixed-effects analysis of FKSI-DRS scores revealed results similar to those for FKSI-15, with no significant difference between the treatment arms (</offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="23401" xml_f="23409" txt_i="15131" txt_f="15139">Figure 2</offsets></xref><offsets xml_i="23416" xml_f="23550" txt_i="15139" txt_f="15273">). Mean FKSI-DRS values for axitinib and sorafenib were similar throughout the study. Baseline values (28.87 and 28.98, respectively; </offsets><xref rid="tbl1" ref-type="table"><offsets xml_i="23584" xml_f="23591" txt_i="15273" txt_f="15280">Table 1</offsets></xref><offsets xml_i="23598" xml_f="23974" txt_i="15280" txt_f="15656">) were maintained throughout the study, but scores worsened at EOT (26.29 and 26.52, respectively). Mean values for 28-day follow-up were 28.26 and 27.52, respectively. Similar to the FKSI-15 analysis of responder status at EOT, FKSI-DRS mean scores for patients who provided follow-up data were higher than those who did not (27.32 and 25.67, respectively; difference, 1.66; </offsets><italic><offsets xml_i="23982" xml_f="23983" txt_i="15656" txt_f="15657">P</offsets></italic><offsets xml_i="23992" xml_f="24001" txt_i="15657" txt_f="15666">=0.0050).</offsets></p><p><offsets xml_i="24008" xml_f="24163" txt_i="15667" txt_f="15822">There was no statistically significant difference in the post-treatment difference between axitinib and sorafenib based on the repeated measures analysis (</offsets><xref rid="tbl2" ref-type="table"><offsets xml_i="24197" xml_f="24204" txt_i="15822" txt_f="15829">Table 2</offsets></xref><offsets xml_i="24211" xml_f="24286" txt_i="15829" txt_f="15904">). As for FKSI-15, there was no significant treatment-by-time interaction (</offsets><italic><offsets xml_i="24294" xml_f="24295" txt_i="15904" txt_f="15905">P</offsets></italic><offsets xml_i="24304" xml_f="24477" txt_i="15905" txt_f="16078">=0.8024), indicating no difference in the course of the treatment effect over the cycles. Most scores were similar between treatments across the nine items of the FKSI-DRS. </offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="24509" xml_f="24517" txt_i="16078" txt_f="16086">Figure 3</offsets></xref><offsets xml_i="24524" xml_f="24691" txt_i="16086" txt_f="16253"> depicts the observed mean difference between treatments in degree of bother with side effects. Patterns in FKSI-DRS scores in subgroups by prior treatment (sunitinib </offsets><italic><offsets xml_i="24699" xml_f="24701" txt_i="16253" txt_f="16255">vs</offsets></italic><offsets xml_i="24710" xml_f="24799" txt_i="16255" txt_f="16344"> cytokine therapy) and MSKCC risk group were similar to those reported above for FKSI-15.</offsets></p></sec><sec><title><offsets xml_i="24821" xml_f="24838" txt_i="16346" txt_f="16363">EQ-5D assessments</offsets></title><p><offsets xml_i="24849" xml_f="25159" txt_i="16364" txt_f="16674">Similar to the FKSI results, observed EQ-5D means were similar until EOT, after which there was a drop when patients typically experienced disease progression. There was no statistically significant difference between axitinib and sorafenib in EQ-5D index scores in the mixed-effects model; (difference, 0.02; </offsets><italic><offsets xml_i="25167" xml_f="25168" txt_i="16674" txt_f="16675">P</offsets></italic><offsets xml_i="25177" xml_f="25186" txt_i="16675" txt_f="16684">=0.1903; </offsets><xref rid="tbl2" ref-type="table"><offsets xml_i="25220" xml_f="25227" txt_i="16684" txt_f="16691">Table 2</offsets></xref><offsets xml_i="25234" xml_f="25286" txt_i="16691" txt_f="16743">) or in the interaction between treatment and time (</offsets><italic><offsets xml_i="25294" xml_f="25295" txt_i="16743" txt_f="16744">P</offsets></italic><offsets xml_i="25304" xml_f="25313" txt_i="16744" txt_f="16753">=0.8048).</offsets></p><p><offsets xml_i="25320" xml_f="25478" txt_i="16754" txt_f="16912">In the EQ-5D health status profile, the proportion of patients with no problems with mobility through cycle 12 was ∼10% higher at every cycle in the axitinib </offsets><italic><offsets xml_i="25486" xml_f="25488" txt_i="16912" txt_f="16914">vs</offsets></italic><offsets xml_i="25497" xml_f="25811" txt_i="16914" txt_f="17228"> the sorafenib arm and was never below 57% and 49% of respondents, respectively. The proportion of patients with no problem with pain/discomfort was similar (30–40%) while on treatment throughout the study for both treatment arms, as was the proportion of patients with no problem with anxiety/depression (50–60%).</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="25861" xml_f="25871" txt_i="17231" txt_f="17241">Discussion</offsets></title><p><offsets xml_i="25882" xml_f="26117" txt_i="17242" txt_f="17477">This study summarises patient-reported outcomes from a randomised phase III study that directly compared axitinib with sorafenib in patients with mRCC following failure of a prior systemic therapy. Efficacy results (reported elsewhere </offsets><xref ref-type="bibr" rid="bib26"><offsets xml_i="26151" xml_f="26156" txt_i="17477" txt_f="17482">Rini </offsets><italic><offsets xml_i="26164" xml_f="26169" txt_i="17482" txt_f="17487">et al</offsets></italic><offsets xml_i="26178" xml_f="26184" txt_i="17487" txt_f="17493">, 2011</offsets></xref><offsets xml_i="26191" xml_f="26440" txt_i="17493" txt_f="17742">) demonstrated that axitinib treatment resulted in significantly longer PFS compared with sorafenib and the analysis of the composite end point of TTD (defined as a decrease in quality of life (worsening of FKSI-15 score), progression or death; see </offsets><xref ref-type="bibr" rid="bib26"><offsets xml_i="26474" xml_f="26479" txt_i="17742" txt_f="17747">Rini </offsets><italic><offsets xml_i="26487" xml_f="26492" txt_i="17747" txt_f="17752">et al</offsets></italic><offsets xml_i="26501" xml_f="26508" txt_i="17752" txt_f="17759"> (2011)</offsets></xref><offsets xml_i="26515" xml_f="26666" txt_i="17759" txt_f="17910"> for further details) demonstrated a statistically significant advantage for axitinib: HR=0.829, 95% confidence interval (CI): 0.701, 0.981; one-sided </offsets><italic><offsets xml_i="26674" xml_f="26675" txt_i="17910" txt_f="17911">P</offsets></italic><offsets xml_i="26684" xml_f="26790" txt_i="17911" txt_f="18017">=0.014. Similarly, a 16% risk reduction in the TTD FKSI-DRS composite end point was observed for axitinib </offsets><italic><offsets xml_i="26798" xml_f="26800" txt_i="18017" txt_f="18019">vs</offsets></italic><offsets xml_i="26809" xml_f="26863" txt_i="18019" txt_f="18073"> sorafenib (HR=0.838, 95% CI: 0.707, 0.993; one-sided </offsets><italic><offsets xml_i="26871" xml_f="26872" txt_i="18073" txt_f="18074">P</offsets></italic><offsets xml_i="26881" xml_f="27094" txt_i="18074" txt_f="18287">=0.0203), highlighting that the delay in disease progression was accompanied by minimal toxicity or worsening of symptoms. These results confirm those of the two single-arm phase II studies in patients with mRCC (</offsets><xref ref-type="bibr" rid="bib33"><offsets xml_i="27128" xml_f="27134" txt_i="18287" txt_f="18293">Trask </offsets><italic><offsets xml_i="27142" xml_f="27147" txt_i="18293" txt_f="18298">et al</offsets></italic><offsets xml_i="27156" xml_f="27162" txt_i="18298" txt_f="18304">, 2008</offsets></xref><offsets xml_i="27169" xml_f="27171" txt_i="18304" txt_f="18306">; </offsets><xref ref-type="bibr" rid="bib27"><offsets xml_i="27205" xml_f="27210" txt_i="18306" txt_f="18311">Rini </offsets><italic><offsets xml_i="27218" xml_f="27223" txt_i="18311" txt_f="18316">et al</offsets></italic><offsets xml_i="27232" xml_f="27238" txt_i="18316" txt_f="18322">, 2009</offsets></xref><offsets xml_i="27245" xml_f="27247" txt_i="18322" txt_f="18324">).</offsets></p><p><offsets xml_i="27254" xml_f="27993" txt_i="18325" txt_f="19064">This report focuses on patient-reported kidney-specific symptoms and functional data. Treatment with axitinib was associated with comparable outcomes to sorafenib, as demonstrated by similar FKSI-15 scores while on treatment. When patients experienced disease progression at EOT, FKSI scores worsened, revealing the impact that progression had on patient HRQoL and also, the value of delaying progression. Scores at 28-days post end-of-treatment were also measured, and revealed a slight improvement (of similar magnitude in both arms) compared with EOT. However, this was likely because responders were healthier than those who did not complete the forms, as the end-of-treatment scores for responders were similar to their day 28 scores.</offsets></p><p><offsets xml_i="28000" xml_f="28101" txt_i="19065" txt_f="19166">Of note, the baseline scores of patients in this study were comparable to the general US population (</offsets><xref ref-type="bibr" rid="bib4"><offsets xml_i="28134" xml_f="28139" txt_i="19166" txt_f="19171">Butt </offsets><italic><offsets xml_i="28147" xml_f="28152" txt_i="19171" txt_f="19176">et al</offsets></italic><offsets xml_i="28161" xml_f="28167" txt_i="19176" txt_f="19182">, 2012</offsets></xref><offsets xml_i="28174" xml_f="29159" txt_i="19182" txt_f="20167">) and, as such, it would be unrealistic to expect an improvement in symptoms/quality of life as can be observed, for example, in lung cancer, where patients are very symptomatic at baseline. In the present study, patients were able to ‘maintain' symptom control while on treatment with both agents; however, when their disease progressed at EOT, there was a meaningful worsening of patient-reported outcomes. In essence, this reflects that patients receiving VEGF TKI treatment (whether sorafenib or axitinib) manage to maintain a relatively low symptom burden, comparable to their pre-treatment condition. This declined significantly at EOT, suggesting that VEGF TKI therapy that delays progression longer would have better value than one associated with a shorter progression-free interval. Understanding the value of PFS is increasingly important because demonstrating an overall survival benefit can be challenging in tumours such as mRCC, where survival post progression is long (</offsets><xref ref-type="bibr" rid="bib1"><offsets xml_i="29192" xml_f="29197" txt_i="20167" txt_f="20172">Amir </offsets><italic><offsets xml_i="29205" xml_f="29210" txt_i="20172" txt_f="20177">et al</offsets></italic><offsets xml_i="29219" xml_f="29225" txt_i="20177" txt_f="20183">, 2012</offsets></xref><offsets xml_i="29232" xml_f="29234" txt_i="20183" txt_f="20185">; </offsets><xref ref-type="bibr" rid="bib12"><offsets xml_i="29268" xml_f="29298" txt_i="20185" txt_f="20215">Fallowfield and Fleissig, 2012</offsets></xref><offsets xml_i="29305" xml_f="29398" txt_i="20215" txt_f="20308">), and it has been suggested delay of symptoms can be just as important as overall survival (</offsets><xref ref-type="bibr" rid="bib1"><offsets xml_i="29431" xml_f="29436" txt_i="20308" txt_f="20313">Amir </offsets><italic><offsets xml_i="29444" xml_f="29449" txt_i="20313" txt_f="20318">et al</offsets></italic><offsets xml_i="29458" xml_f="29464" txt_i="20318" txt_f="20324">, 2012</offsets></xref><offsets xml_i="29471" xml_f="29473" txt_i="20324" txt_f="20326">).</offsets></p><p><offsets xml_i="29480" xml_f="29545" txt_i="20327" txt_f="20392">The FKSI-DRS measures intend to assess disease-related symptoms (</offsets><xref ref-type="bibr" rid="bib6"><offsets xml_i="29578" xml_f="29584" txt_i="20392" txt_f="20398">Cella </offsets><italic><offsets xml_i="29592" xml_f="29597" txt_i="20398" txt_f="20403">et al</offsets></italic><offsets xml_i="29606" xml_f="29612" txt_i="20403" txt_f="20409">, 2007</offsets></xref><offsets xml_i="29619" xml_f="30254" txt_i="20409" txt_f="21044">). In oncology clinical trials, symptoms represent the most proximal outcome of treatment for patients with advanced RCC and are most likely to detect differences between treatments. Information on patient-reported symptoms and functioning, combined with clinical end points, can assist patients and physicians in selecting the most effective treatments. Given the availability of new therapies for treating mRCC, patients need to understand the trade-off between PFS and treatment-related toxicity. In the present study, most scores across the nine items of the FKSI-DRS were similar among patients treated with axitinib or sorafenib.</offsets></p><p><offsets xml_i="30261" xml_f="30401" txt_i="21045" txt_f="21185">It is difficult to systematically compare results of axitinib studies with those of other approved second-line treatments for advanced RCC (</offsets><xref ref-type="bibr" rid="bib3"><offsets xml_i="30434" xml_f="30443" txt_i="21185" txt_f="21194">Bukowski </offsets><italic><offsets xml_i="30451" xml_f="30456" txt_i="21194" txt_f="21199">et al</offsets></italic><offsets xml_i="30465" xml_f="30471" txt_i="21199" txt_f="21205">, 2007</offsets></xref><offsets xml_i="30478" xml_f="30480" txt_i="21205" txt_f="21207">; </offsets><xref ref-type="bibr" rid="bib8"><offsets xml_i="30513" xml_f="30519" txt_i="21207" txt_f="21213">Eisen </offsets><italic><offsets xml_i="30527" xml_f="30532" txt_i="21213" txt_f="21218">et al</offsets></italic><offsets xml_i="30541" xml_f="30547" txt_i="21218" txt_f="21224">, 2008</offsets></xref><offsets xml_i="30554" xml_f="30556" txt_i="21224" txt_f="21226">; </offsets><xref ref-type="bibr" rid="bib2"><offsets xml_i="30589" xml_f="30598" txt_i="21226" txt_f="21235">Beaumont </offsets><italic><offsets xml_i="30606" xml_f="30611" txt_i="21235" txt_f="21240">et al</offsets></italic><offsets xml_i="30620" xml_f="30626" txt_i="21240" txt_f="21246">, 2011</offsets></xref><offsets xml_i="30633" xml_f="30965" txt_i="21246" txt_f="21578">) owing to differences in the FKSI questionnaire versions and analyses used, patient populations studied in the second-line setting and compliance with patient-reported data collection. This is the first trial comparing two VEGFR-TKI agents head-to-head in the second-line mRCC setting. A number of studies have used placebo or IFN-</offsets><italic><offsets xml_i="30973" xml_f="30974" txt_i="21578" txt_f="21579">α</offsets></italic><offsets xml_i="30983" xml_f="31032" txt_i="21579" txt_f="21628"> as comparators. For example, in a recent study (</offsets><xref ref-type="bibr" rid="bib2"><offsets xml_i="31065" xml_f="31074" txt_i="21628" txt_f="21637">Beaumont </offsets><italic><offsets xml_i="31082" xml_f="31087" txt_i="21637" txt_f="21642">et al</offsets></italic><offsets xml_i="31096" xml_f="31102" txt_i="21642" txt_f="21648">, 2011</offsets></xref><offsets xml_i="31109" xml_f="31348" txt_i="21648" txt_f="21887">) in patients with advanced RCC, there were no statistically significant differences in FKSI-DRS scores in longitudinal analyses for everolimus compared with placebo. Similar findings were observed in a study of sorafenib in advanced RCC (</offsets><xref ref-type="bibr" rid="bib3"><offsets xml_i="31381" xml_f="31390" txt_i="21887" txt_f="21896">Bukowski </offsets><italic><offsets xml_i="31398" xml_f="31403" txt_i="21896" txt_f="21901">et al</offsets></italic><offsets xml_i="31412" xml_f="31418" txt_i="21901" txt_f="21907">, 2007</offsets></xref><offsets xml_i="31425" xml_f="31928" txt_i="21907" txt_f="22410">), which reported that there were no differences between sorafenib and placebo in mean scores for either the Functional Assessment of Cancer Therapy–General or the FKSI-10. Based on the results of the present study, axitinib has comparable HRQoL outcomes and better PFS compared with sorafenib in patients with advanced RCC, supported by the previously reported 16–17% (statistically significant) decrease in the composite TTD end point comprises risk of progression, death or worsening of FKSI scores (</offsets><xref ref-type="bibr" rid="bib26"><offsets xml_i="31962" xml_f="31967" txt_i="22410" txt_f="22415">Rini </offsets><italic><offsets xml_i="31975" xml_f="31980" txt_i="22415" txt_f="22420">et al</offsets></italic><offsets xml_i="31989" xml_f="31995" txt_i="22420" txt_f="22426">, 2011</offsets></xref><offsets xml_i="32002" xml_f="33046" txt_i="22426" txt_f="23470">). Several limitations should be considered when interpreting the results of this analysis. The open-label trial design could be considered as a limitation because investigators and patients could be biased in their self-reported assessments based on treatment expectations. Although open-label, the study had an active comparator; therefore, the potential for bias is reduced compared with a placebo-controlled study. Furthermore, all analyses were pre-specified secondary end points of the AXIS trial. Differential dropout rates were observed. As patients in the sorafenib arm had higher rates of study discontinuation, we conducted additional statistical modelling to address this potential imbalance and found similar results. However, missing data complicate interpretation of patient-reported outcomes, and the true effect of sorafenib on HRQoL may not have been assessed. Also, the inclusion of other questionnaires targeting an expanded list of side effects may have permitted more information to be collected about this class of agent.</offsets></p><p><offsets xml_i="33053" xml_f="34220" txt_i="23471" txt_f="24638">In summary, this clinical trial compared two VEGFR TKIs as second-line therapy for mRCC. One goal in mRCC treatment is to maintain patient symptoms or HRQoL for as long as possible, and thereby delay worsening. Clearly, when patients are assessed at EOT, their FKSI scores are worse than they were while on treatment. This is likely to be related to tumour progression, although the impact on HRQoL of factors such as unresolved adverse events, accumulating toxicity and emotional response cannot be ruled out. Given that disease-related symptoms and HRQoL are better when patients are on treatment and progression-free and that patients receiving axitinib have significantly longer PFS compared with sorafenib, patients who receive axitinib are more likely to have longer symptom ‘control' that is not offset by a worsening of patient-reported outcomes. Patient-reported outcomes provide clinicians and patients with supplemental information on the overall impact of disease-related symptoms, progression and toxicity on functioning and well-being and can help patients and their providers discuss treatment options with more information than toxicity and PFS alone.</offsets></p></sec></body><back><ack><p>This study was sponsored by Pfizer Inc. Medical writing support was provided by Dennis Revicki, PhD, at United Biosource Corporation and Helen Jones, PhD, at UBC Scientific Solutions and was funded by Pfizer Inc.</p></ack><fn-group><fn><p>This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.</p></fn><fn><p><bold>Prior presentation:</bold> The work presented in this manuscript is original and has not been published elsewhere. Portions of the data have previously been presented as listed below. (1) D Cella, B Escudier, BI Rini, <italic>et al.</italic> Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib <italic>versus</italic> sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC). Oral presentation at American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA, 3–7 June 2011. (2) D Cella, B Escudier, B Rini <italic>et al.</italic> Time to deterioration (TTD) in patient-reported outcomes in phase 3 AXIS trial of axitinib <italic>vs</italic> sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC). Poster presentation at European Society for Medical Oncology 36th Congress–ECCO 16 and ESMO 36, Stockholm, Sweden, 23–27 September 2011.</p></fn></fn-group><notes><p>DC has served as a consultant for and received research funding from Pfizer, AVEO, Bayer, GlaxoSmithKline, and Novartis. BE has received honoraria from AVEO, Bayer, GlaxoSmithKline, Novartis, and Pfizer. BRi has served as a consultant for and received research funding from Pfizer. CC, HB, JT, Bro, and SK are employees of and shareholders in Pfizer Inc. RM has served as a consultant for Pfizer.</p></notes><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amir</surname><given-names>E</given-names></name><name><surname>Seruga</surname><given-names>B</given-names></name><name><surname>Kwong</surname><given-names>R</given-names></name><name><surname>Tannock</surname><given-names>IF</given-names></name><name><surname>Ocana</surname><given-names>A</given-names></name></person-group><year>2012</year><article-title>Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer</article-title><source>Eur J Cancer</source><volume>48</volume><fpage>385</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">22115991</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaumont</surname><given-names>JL</given-names></name><name><surname>Butt</surname><given-names>Z</given-names></name><name><surname>Baladi</surname><given-names>J</given-names></name><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Haas</surname><given-names>T</given-names></name><name><surname>Hollaender</surname><given-names>N</given-names></name><name><surname>Kay</surname><given-names>A</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name></person-group><year>2011</year><article-title>Patient-reported outcomes in a phase III Study of everolimus <italic>versus</italic> placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy</article-title><source>Oncologist</source><volume>16</volume><fpage>632</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">21459902</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bukowski</surname><given-names>R</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Gondek</surname><given-names>K</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name></person-group><year>2007</year><article-title>Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer</article-title><source>Am J Clin Oncol</source><volume>30</volume><fpage>220</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">17551296</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butt</surname><given-names>Z</given-names></name><name><surname>Peipert</surname><given-names>J</given-names></name><name><surname>Webster</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name></person-group><year>2012</year><article-title>General population norms for the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)</article-title><source>Cancer</source><volume>119</volume><fpage>429</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">22778010</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>D</given-names></name></person-group><year>2009</year><article-title>Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes</article-title><source>Cancer Treat Rev</source><volume>35</volume><fpage>733</fpage><lpage>737</lpage><pub-id pub-id-type="pmid">19699588</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Yount</surname><given-names>S</given-names></name><name><surname>Brucker</surname><given-names>PS</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Bukowski</surname><given-names>R</given-names></name><name><surname>Vogelzang</surname><given-names>N</given-names></name><name><surname>Bro</surname><given-names>WP</given-names></name></person-group><year>2007</year><article-title>Development and validation of a scale to measure disease-related symptoms of kidney cancer</article-title><source>Value Health</source><volume>10</volume><fpage>285</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">17645683</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Yount</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Dhanda</surname><given-names>R</given-names></name><name><surname>Gondek</surname><given-names>K</given-names></name><name><surname>Langefeld</surname><given-names>K</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Bro</surname><given-names>WP</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><name><surname>Bukowski</surname><given-names>R</given-names></name></person-group><year>2006</year><article-title>Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)</article-title><source>J Support Oncol</source><volume>4</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">16669463</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisen</surname><given-names>T</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Gravis</surname><given-names>G</given-names></name><name><surname>Heinzer</surname><given-names>H</given-names></name><name><surname>Middleton</surname><given-names>R</given-names></name><name><surname>Cihon</surname><given-names>F</given-names></name><name><surname>Anderson</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Bukowski</surname><given-names>R</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name></person-group><year>2008</year><article-title>Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial</article-title><source>J Natl Cancer Inst</source><volume>100</volume><fpage>1454</fpage><lpage>1463</lpage><pub-id pub-id-type="pmid">18840822</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Eisen</surname><given-names>T</given-names></name><name><surname>Stadler</surname><given-names>WM</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Siebels</surname><given-names>M</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Chevreau</surname><given-names>C</given-names></name><name><surname>Solska</surname><given-names>E</given-names></name><name><surname>Desai</surname><given-names>AA</given-names></name><name><surname>Rolland</surname><given-names>F</given-names></name><name><surname>Demkow</surname><given-names>T</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Freeman</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>B</given-names></name><name><surname>Shan</surname><given-names>M</given-names></name><name><surname>Simantov</surname><given-names>R</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name></person-group><year>2007a</year><article-title>Sorafenib in advanced clear-cell renal-cell carcinoma</article-title><source>N Engl J Med</source><volume>356</volume><fpage>125</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">17215530</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Eisen</surname><given-names>T</given-names></name><name><surname>Stadler</surname><given-names>WM</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Staehler</surname><given-names>M</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Chevreau</surname><given-names>C</given-names></name><name><surname>Desai</surname><given-names>AA</given-names></name><name><surname>Rolland</surname><given-names>F</given-names></name><name><surname>Demkow</surname><given-names>T</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>S</given-names></name><name><surname>Hofilena</surname><given-names>G</given-names></name><name><surname>Shan</surname><given-names>M</given-names></name><name><surname>Pena</surname><given-names>C</given-names></name><name><surname>Lathia</surname><given-names>C</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name></person-group><year>2009</year><article-title>Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial</article-title><source>J Clin Oncol</source><volume>27</volume><fpage>3312</fpage><lpage>3318</lpage><pub-id pub-id-type="pmid">19451442</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Pluzanska</surname><given-names>A</given-names></name><name><surname>Koralewski</surname><given-names>P</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name><name><surname>Bracarda</surname><given-names>S</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Chevreau</surname><given-names>C</given-names></name><name><surname>Filipek</surname><given-names>M</given-names></name><name><surname>Melichar</surname><given-names>B</given-names></name><name><surname>Bajetta</surname><given-names>E</given-names></name><name><surname>Gorbunova</surname><given-names>V</given-names></name><name><surname>Bay</surname><given-names>JO</given-names></name><name><surname>Bodrogi</surname><given-names>I</given-names></name><name><surname>Jagiello-Gruszfeld</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>N</given-names></name></person-group><year>2007b</year><article-title>Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial</article-title><source>Lancet</source><volume>370</volume><fpage>2103</fpage><lpage>2111</lpage><pub-id pub-id-type="pmid">18156031</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallowfield</surname><given-names>LJ</given-names></name><name><surname>Fleissig</surname><given-names>A</given-names></name></person-group><year>2012</year><article-title>The value of progression-free survival to patients with advanced-stage cancer</article-title><source>Nat Rev</source><volume>9</volume><fpage>41</fpage><lpage>47</lpage></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>JD</given-names></name><name><surname>Li</surname><given-names>JZ</given-names></name><name><surname>Russell</surname><given-names>MW</given-names></name><name><surname>Charbonneau</surname><given-names>C</given-names></name></person-group><year>2008</year><article-title>Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review</article-title><source>Cancer Treat Rev</source><volume>34</volume><fpage>193</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">18313224</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>G</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Robinson</surname><given-names>D</given-names><suffix>Jr.</suffix></name><name><surname>Mahadevia</surname><given-names>PJ</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Revicki</surname><given-names>DA</given-names></name></person-group><year>2007</year><article-title>Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index</article-title><source>Health Qual Life Outcomes</source><volume>5</volume><fpage>34</fpage><pub-id pub-id-type="pmid">17570854</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hedeker</surname><given-names>D</given-names></name><name><surname>Gibbons</surname><given-names>R</given-names></name></person-group><year>2006</year><source>Longitudinal Data Analysisedn</source><publisher-name>John Wiley &amp; Sons: Hoboken</publisher-name></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heng</surname><given-names>DY</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Regan</surname><given-names>MM</given-names></name><name><surname>Warren</surname><given-names>MA</given-names></name><name><surname>Golshayan</surname><given-names>AR</given-names></name><name><surname>Sahi</surname><given-names>C</given-names></name><name><surname>Eigl</surname><given-names>BJ</given-names></name><name><surname>Ruether</surname><given-names>JD</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name><name><surname>North</surname><given-names>S</given-names></name><name><surname>Venner</surname><given-names>P</given-names></name><name><surname>Knox</surname><given-names>JJ</given-names></name><name><surname>Chi</surname><given-names>KN</given-names></name><name><surname>Kollmannsberger</surname><given-names>C</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Oh</surname><given-names>WK</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name></person-group><year>2009</year><article-title>Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study</article-title><source>J Clin Oncol</source><volume>27</volume><fpage>5794</fpage><lpage>5799</lpage><pub-id pub-id-type="pmid">19826129</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu-Lowe</surname><given-names>DD</given-names></name><name><surname>Zou</surname><given-names>HY</given-names></name><name><surname>Grazzini</surname><given-names>ML</given-names></name><name><surname>Hallin</surname><given-names>ME</given-names></name><name><surname>Wickman</surname><given-names>GR</given-names></name><name><surname>Amundson</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Rewolinski</surname><given-names>DA</given-names></name><name><surname>Yamazaki</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>EY</given-names></name><name><surname>McTigue</surname><given-names>MA</given-names></name><name><surname>Murray</surname><given-names>BW</given-names></name><name><surname>Kania</surname><given-names>RS</given-names></name><name><surname>O'Connor</surname><given-names>P</given-names></name><name><surname>Shalinsky</surname><given-names>DR</given-names></name><name><surname>Bender</surname><given-names>SL</given-names></name></person-group><year>2008</year><article-title>Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3</article-title><source>Clin Cancer Res</source><volume>14</volume><fpage>7272</fpage><lpage>7283</lpage><pub-id pub-id-type="pmid">19010843</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudes</surname><given-names>G</given-names></name><name><surname>Carducci</surname><given-names>M</given-names></name><name><surname>Tomczak</surname><given-names>P</given-names></name><name><surname>Dutcher</surname><given-names>J</given-names></name><name><surname>Figlin</surname><given-names>R</given-names></name><name><surname>Kapoor</surname><given-names>A</given-names></name><name><surname>Staroslawska</surname><given-names>E</given-names></name><name><surname>Sosman</surname><given-names>J</given-names></name><name><surname>McDermott</surname><given-names>D</given-names></name><name><surname>Bodrogi</surname><given-names>I</given-names></name><name><surname>Kovacevic</surname><given-names>Z</given-names></name><name><surname>Lesovoy</surname><given-names>V</given-names></name><name><surname>Schmidt-Wolf</surname><given-names>IG</given-names></name><name><surname>Barbarash</surname><given-names>O</given-names></name><name><surname>Gokmen</surname><given-names>E</given-names></name><name><surname>O'Toole</surname><given-names>T</given-names></name><name><surname>Lustgarten</surname><given-names>S</given-names></name><name><surname>Moore</surname><given-names>L</given-names></name><name><surname>Motzer</surname><given-names>RJ</given-names></name></person-group><year>2007</year><article-title>Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma</article-title><source>N Engl J Med</source><volume>356</volume><fpage>2271</fpage><lpage>2281</lpage><pub-id pub-id-type="pmid">17538086</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kind</surname><given-names>P</given-names></name></person-group><year>1996</year><source>The EuroQol Instrument: An Index of Health-Related Quality of Life. Quality of Life and Pharmacoeconomics in Clinical Trials</source>In Spilker B (ed.)2nd edn.<publisher-name>Lippicott-Raven: Philadephia</publisher-name></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>JS</given-names></name><name><surname>Belldegrun</surname><given-names>AS</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name></person-group><year>2004</year><article-title>Advances in immune-based therapies of renal cell carcinoma</article-title><source>Expert Rev Anticancer Ther</source><volume>4</volume><fpage>1081</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">15606335</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linehan</surname><given-names>WM</given-names></name><name><surname>Zbar</surname><given-names>B</given-names></name></person-group><year>2004</year><article-title>Focus on kidney cancer</article-title><source>Cancer Cell</source><volume>6</volume><fpage>223</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">15380513</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Bacik</surname><given-names>J</given-names></name><name><surname>Schwartz</surname><given-names>LH</given-names></name><name><surname>Reuter</surname><given-names>V</given-names></name><name><surname>Russo</surname><given-names>P</given-names></name><name><surname>Marion</surname><given-names>S</given-names></name><name><surname>Mazumdar</surname><given-names>M</given-names></name></person-group><year>2004</year><article-title>Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma</article-title><source>J Clin Oncol</source><volume>22</volume><fpage>454</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">14752067</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Bracarda</surname><given-names>S</given-names></name><name><surname>Grunwald</surname><given-names>V</given-names></name><name><surname>Thompson</surname><given-names>JA</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name><name><surname>Hollaender</surname><given-names>N</given-names></name><name><surname>Kay</surname><given-names>A</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name></person-group><year>2010</year><article-title>Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors</article-title><source>Cancer</source><volume>116</volume><fpage>4256</fpage><lpage>4265</lpage><pub-id pub-id-type="pmid">20549832</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Bracarda</surname><given-names>S</given-names></name><name><surname>Grunwald</surname><given-names>V</given-names></name><name><surname>Thompson</surname><given-names>JA</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name><name><surname>Hollaender</surname><given-names>N</given-names></name><name><surname>Urbanowitz</surname><given-names>G</given-names></name><name><surname>Berg</surname><given-names>WJ</given-names></name><name><surname>Kay</surname><given-names>A</given-names></name><name><surname>Lebwohl</surname><given-names>D</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name></person-group><year>2008</year><article-title>Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial</article-title><source>Lancet</source><volume>372</volume><fpage>449</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">18653228</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Tomczak</surname><given-names>P</given-names></name><name><surname>Michaelson</surname><given-names>MD</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Rixe</surname><given-names>O</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>ST</given-names></name><name><surname>Chen</surname><given-names>I</given-names></name><name><surname>Bycott</surname><given-names>PW</given-names></name><name><surname>Baum</surname><given-names>CM</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name></person-group><year>2007</year><article-title>Sunitinib <italic>versus</italic> interferon alfa in metastatic renal-cell carcinoma</article-title><source>N Engl J Med</source><volume>356</volume><fpage>115</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">17215529</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Tomczak</surname><given-names>P</given-names></name><name><surname>Kaprin</surname><given-names>A</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Michaelson</surname><given-names>MD</given-names></name><name><surname>Gorbunova</surname><given-names>VA</given-names></name><name><surname>Gore</surname><given-names>ME</given-names></name><name><surname>Rusakov</surname><given-names>IG</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Ou</surname><given-names>YC</given-names></name><name><surname>Castellano</surname><given-names>D</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Uemura</surname><given-names>H</given-names></name><name><surname>Tarazi</surname><given-names>J</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Rosbrook</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Motzer</surname><given-names>RJ</given-names></name></person-group><year>2011</year><article-title>Comparative effectiveness of axitinib <italic>versus</italic> sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial</article-title><source>Lancet</source><volume>378</volume><fpage>1931</fpage><lpage>1939</lpage><pub-id pub-id-type="pmid">22056247</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Wilding</surname><given-names>G</given-names></name><name><surname>Hudes</surname><given-names>G</given-names></name><name><surname>Stadler</surname><given-names>WM</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Tarazi</surname><given-names>J</given-names></name><name><surname>Rosbrook</surname><given-names>B</given-names></name><name><surname>Trask</surname><given-names>PC</given-names></name><name><surname>Wood</surname><given-names>L</given-names></name><name><surname>Dutcher</surname><given-names>JP</given-names></name></person-group><year>2009</year><article-title>Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma</article-title><source>J Clin Oncol</source><volume>27</volume><fpage>4462</fpage><lpage>4468</lpage><pub-id pub-id-type="pmid">19652060</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rixe</surname><given-names>O</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Michaelson</surname><given-names>MD</given-names></name><name><surname>Wilding</surname><given-names>G</given-names></name><name><surname>Hudes</surname><given-names>GR</given-names></name><name><surname>Bolte</surname><given-names>O</given-names></name><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Bycott</surname><given-names>P</given-names></name><name><surname>Liau</surname><given-names>KF</given-names></name><name><surname>Freddo</surname><given-names>J</given-names></name><name><surname>Trask</surname><given-names>PC</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name></person-group><year>2007</year><article-title>Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study</article-title><source>Lancet Oncol</source><volume>8</volume><fpage>975</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">17959415</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>D</given-names></name></person-group><year>1976</year><article-title>Inference and missing data</article-title><source>Biometrika</source><volume>72</volume><fpage>359</fpage><lpage>364</lpage></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Willett</surname><given-names>J</given-names></name></person-group><year>2003</year><source>Applied Longitudinal Data Analysis: Modeling Change and Event Occurrenceedn</source><publisher-name>Oxford University Press: New York</publisher-name></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sternberg</surname><given-names>CN</given-names></name><name><surname>Davis</surname><given-names>ID</given-names></name><name><surname>Mardiak</surname><given-names>J</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Wagstaff</surname><given-names>J</given-names></name><name><surname>Barrios</surname><given-names>CH</given-names></name><name><surname>Salman</surname><given-names>P</given-names></name><name><surname>Gladkov</surname><given-names>OA</given-names></name><name><surname>Kavina</surname><given-names>A</given-names></name><name><surname>Zarba</surname><given-names>JJ</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>McCann</surname><given-names>L</given-names></name><name><surname>Pandite</surname><given-names>L</given-names></name><name><surname>Roychowdhury</surname><given-names>DF</given-names></name><name><surname>Hawkins</surname><given-names>RE</given-names></name></person-group><year>2010</year><article-title>Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial</article-title><source>J Clin Oncol</source><volume>28</volume><fpage>1061</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">20100962</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Arbuck</surname><given-names>SG</given-names></name><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Wanders</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>RS</given-names></name><name><surname>Rubinstein</surname><given-names>L</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Van Glabbeke</surname><given-names>M</given-names></name><name><surname>van Oosterom</surname><given-names>AT</given-names></name><name><surname>Christian</surname><given-names>MC</given-names></name><name><surname>Gwyther</surname><given-names>SG</given-names></name></person-group><year>2000</year><article-title>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</article-title><source>J Natl Cancer Inst</source><volume>92</volume><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">10655437</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trask</surname><given-names>PC</given-names></name><name><surname>Bushmakin</surname><given-names>AG</given-names></name><name><surname>Cappelleri</surname><given-names>JC</given-names></name><name><surname>Bycott</surname><given-names>P</given-names></name><name><surname>Liau</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name></person-group><year>2008</year><article-title>Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib</article-title><source>Acta Oncol (Stockholm, Sweden)</source><volume>47</volume><fpage>843</fpage><lpage>851</lpage></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Troxel</surname><given-names>AB</given-names></name><name><surname>Fairclough</surname><given-names>DL</given-names></name><name><surname>Curran</surname><given-names>D</given-names></name><name><surname>Hahn</surname><given-names>EA</given-names></name></person-group><year>1998</year><article-title>Statistical analysis of quality of life with missing data in cancer clinical trials</article-title><source>Stat Med</source><volume>17</volume><fpage>653</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">9549814</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>LI</given-names></name><name><surname>Wenzel</surname><given-names>L</given-names></name><name><surname>Shaw</surname><given-names>E</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name></person-group><year>2007</year><article-title>Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions</article-title><source>J Clin Oncol</source><volume>25</volume><fpage>5058</fpage><lpage>5062</lpage><pub-id pub-id-type="pmid">17991921</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p><bold>Mean FKSI-15 scores over the course of the study.</bold> Dotted line represents US population mean. Point estimates for end of treatment scores for axitinib and sorafenib arms are virtually identical and therefore indistinguishable. FKSI-15, Functional Assessment of Cancer Therapy Kidney Symptom Index-15; s.e., standard error.</p></caption><graphic xlink:href="bjc2013145f1"></graphic></fig><fig id="fig2"><label>Figure 2</label><caption><p><bold>Mean FKSI-DRS scores over the course of the study.</bold> Dotted line represents US population mean. FKSI-DRS, Functional Assessment of Cancer Therapy–Kidney Cancer Symptom Index-disease-related symptoms subscale; s.e., standard error.</p></caption><graphic xlink:href="bjc2013145f2"></graphic></fig><fig id="fig3"><label>Figure 3</label><caption><p><bold>Response to individual FKSI question, ‘I am bothered by side effects of treatment.'</bold> EOT, end of treatment; FKSI, Functional Assessment of Cancer Therapy–Kidney Cancer Symptom Index.</p></caption><graphic xlink:href="bjc2013145f3"></graphic></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Baseline characteristics<xref ref-type="fn" rid="t1-fn2">a</xref></title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> <hr></hr></th><th align="center" valign="top" charoff="50"><bold>Axitinib</bold><hr></hr></th><th align="center" valign="top" charoff="50"><bold>Sorafenib</bold><hr></hr></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Variable</bold></th><th align="center" valign="top" charoff="50"><italic><bold>n</bold></italic><bold>=361</bold></th><th align="center" valign="top" charoff="50"><italic><bold>n</bold></italic><bold>=362</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Age, years, median (range)<hr></hr></td><td align="center" valign="top" charoff="50">61 (20–82)<hr></hr></td><td align="center" valign="top" charoff="50">61 (22–80)<hr></hr></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Gender</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Male</td><td align="center" valign="top" charoff="50">265 (73)</td><td align="center" valign="top" charoff="50">258 (71)</td></tr><tr><td align="left" valign="top" charoff="50">Female<hr></hr></td><td align="center" valign="top" charoff="50">96 (27)<hr></hr></td><td align="center" valign="top" charoff="50">104 (29)<hr></hr></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Race</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">White</td><td align="center" valign="top" charoff="50">278 (77)</td><td align="center" valign="top" charoff="50">269 (74)</td></tr><tr><td align="left" valign="top" charoff="50">Black</td><td align="center" valign="top" charoff="50">1 (&lt;1)</td><td align="center" valign="top" charoff="50">4 (1)</td></tr><tr><td align="left" valign="top" charoff="50">Asian</td><td align="center" valign="top" charoff="50">77 (21)</td><td align="center" valign="top" charoff="50">81 (22)</td></tr><tr><td align="left" valign="top" charoff="50">Other<hr></hr></td><td align="center" valign="top" charoff="50">5 (1)<hr></hr></td><td align="center" valign="top" charoff="50">8 (2)<hr></hr></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>ECOG performance status</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">195 (54)</td><td align="center" valign="top" charoff="50">200 (55)</td></tr><tr><td align="left" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">162 (45)</td><td align="center" valign="top" charoff="50">160 (44)</td></tr><tr><td align="left" valign="top" charoff="50">&gt;1<hr></hr></td><td align="center" valign="top" charoff="50">1 (&lt;1)<xref ref-type="fn" rid="t1-fn3">b</xref><hr></hr></td><td align="center" valign="top" charoff="50">0<hr></hr></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>MSKCC risk group</bold><xref ref-type="fn" rid="t1-fn4">c</xref> (<xref ref-type="bibr" rid="bib22">Motzer <italic>et al</italic>, 2004</xref>)<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">0 (favourable)</td><td align="center" valign="top" charoff="50">100 (28)</td><td align="center" valign="top" charoff="50">101 (28)</td></tr><tr><td align="left" valign="top" charoff="50">1–2 (intermediate)</td><td align="center" valign="top" charoff="50">134 (37)</td><td align="center" valign="top" charoff="50">130 (36)</td></tr><tr><td align="left" valign="top" charoff="50">⩾3 (poor)</td><td align="center" valign="top" charoff="50">118 (33)</td><td align="center" valign="top" charoff="50">120 (33)</td></tr><tr><td align="left" valign="top" charoff="50">NA<hr></hr></td><td align="center" valign="top" charoff="50">9 (2.5)<hr></hr></td><td align="center" valign="top" charoff="50">11 (3.0)<hr></hr></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Heng</bold>
<italic>et al</italic>
<bold>risk factors</bold> (<xref ref-type="bibr" rid="bib16">Heng <italic>et al</italic>, 2009</xref>)<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">0 (favourable)</td><td align="center" valign="top" charoff="50">66 (18)</td><td align="center" valign="top" charoff="50">79 (22)</td></tr><tr><td align="left" valign="top" charoff="50">1–2 (intermediate)</td><td align="center" valign="top" charoff="50">236 (65)</td><td align="center" valign="top" charoff="50">225 (62)</td></tr><tr><td align="left" valign="top" charoff="50">⩾3 (poor)</td><td align="center" valign="top" charoff="50">37 (10)</td><td align="center" valign="top" charoff="50">34 (9)</td></tr><tr><td align="left" valign="top" charoff="50">N/A<hr></hr></td><td align="center" valign="top" charoff="50">22 (6)<hr></hr></td><td align="center" valign="top" charoff="50">24 (7)<hr></hr></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Prior systemic therapy</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Sunitinib</td><td align="center" valign="top" charoff="50">194 (54)</td><td align="center" valign="top" charoff="50">195 (54)</td></tr><tr><td align="left" valign="top" charoff="50">Cytokines</td><td align="center" valign="top" charoff="50">126 (35)</td><td align="center" valign="top" charoff="50">125 (35)</td></tr><tr><td align="left" valign="top" charoff="50">Bevacizumab</td><td align="center" valign="top" charoff="50">29 (8)</td><td align="center" valign="top" charoff="50">30 (8)</td></tr><tr><td align="left" valign="top" charoff="50">Temsirolimus<hr></hr></td><td align="center" valign="top" charoff="50">12 (3)<hr></hr></td><td align="center" valign="top" charoff="50">12 (3)<hr></hr></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Baseline FKSI-15 score</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50"><italic>N</italic></td><td align="center" valign="top" charoff="50">346</td><td align="center" valign="top" charoff="50">342</td></tr><tr><td align="left" valign="top" charoff="50">Observed mean (s.d.)<hr></hr></td><td align="center" valign="top" charoff="50">43.20 (8.42)<hr></hr></td><td align="center" valign="top" charoff="50">43.34 (8.16)<hr></hr></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Baseline FKSI-DRS score</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50"><italic>N</italic></td><td align="center" valign="top" charoff="50">346</td><td align="center" valign="top" charoff="50">341</td></tr><tr><td align="left" valign="top" charoff="50">Observed mean (s.d.)</td><td align="center" valign="top" charoff="50">28.87 (5.19)</td><td align="center" valign="top" charoff="50">28.98 (5.19)</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: ECOG=Eastern Cooperative Oncology Group; FKSI=Functional Assessment of Cancer Therapy Kidney Symptom Index; FKSI-DRS=Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease-Related Symptoms; MSKCC=Memorial Sloan-Kettering Cancer Center; s.d.=standard deviation.</p></fn><fn id="t1-fn2"><label>a</label><p>Values are <italic>n</italic> (%) unless otherwise noted.</p></fn><fn id="t1-fn3"><label>b</label><p>Protocol violation.</p></fn><fn id="t1-fn4"><label>c</label><p>MSKCC risk groups were derived using three risk factors: haemoglobin (⩽13 <italic>vs</italic> &gt;13 g dl<sup>−1</sup> for males and ⩽11.5 <italic>vs</italic> &gt;11.5 g dl<sup>−1</sup> for females), ‘corrected' calcium (&lt;10 <italic>vs</italic> ⩾10 mg dl<sup>−1</sup>) and ECOG performance status (0 <italic>vs</italic> 1). Risk groups were defined as favourable (0 factors), intermediate (1 factor), or poor (2–3 factors).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Treatment differences for PRO instruments</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="2" align="center" valign="top" charoff="50"><bold>Estimated mean</bold></th><th colspan="3" align="center" valign="top" charoff="50"> </th></tr><tr><th align="left" valign="top" charoff="50"><bold>Instrument</bold></th><th align="center" valign="top" charoff="50"><bold>Axitinib (</bold><italic><bold>n</bold></italic><bold>=361)</bold></th><th align="center" valign="top" charoff="50"><bold>Sorafenib (</bold><italic><bold>n</bold></italic><bold>=362)</bold></th><th align="center" valign="top" charoff="50"><bold>Difference</bold></th><th align="center" valign="top" charoff="50"><bold>95% CI</bold></th><th align="center" valign="top" charoff="50"><italic><bold>P</bold></italic><bold>-value</bold></th></tr></thead><tbody valign="top"><tr><td colspan="6" align="left" valign="top" charoff="50"><bold>FKSI-15</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Treatment</td><td align="char" valign="top" char="." charoff="50">42.21</td><td align="char" valign="top" char="." charoff="50">41.86</td><td align="char" valign="top" char="." charoff="50">0.35</td><td align="center" valign="top" charoff="50">−0.63, 1.34</td><td align="center" valign="top" charoff="50">0.4833</td></tr><tr><td align="left" valign="top" charoff="50">Treatment-by-time<hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td><td align="center" valign="top" charoff="50">0.3943<hr></hr></td></tr><tr><td colspan="6" align="left" valign="top" charoff="50"><bold>FKSI-DRS</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Treatment</td><td align="char" valign="top" char="." charoff="50">28.56</td><td align="char" valign="top" char="." charoff="50">28.44</td><td align="char" valign="top" char="." charoff="50">0.12</td><td align="center" valign="top" charoff="50">−0.45, 0.69</td><td align="center" valign="top" charoff="50">0.6746</td></tr><tr><td align="left" valign="top" charoff="50">Treatment-by-time<hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td><td align="center" valign="top" charoff="50">0.8024<hr></hr></td></tr><tr><td colspan="6" align="left" valign="top" charoff="50"><bold>EQ-5D</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Treatment</td><td align="char" valign="top" char="." charoff="50">0.71</td><td align="char" valign="top" char="." charoff="50">0.69</td><td align="char" valign="top" char="." charoff="50">0.02</td><td align="char" valign="top" char="." charoff="50">−0.01, 0.05</td><td align="center" valign="top" charoff="50">0.1903</td></tr><tr><td align="left" valign="top" charoff="50">Treatment-by-time<hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td><td align="center" valign="top" charoff="50"> <hr></hr></td><td align="center" valign="top" charoff="50">0.8048<hr></hr></td></tr><tr><td colspan="6" align="left" valign="top" charoff="50"><bold>EQ-5D VAS</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Treatment</td><td align="char" valign="top" char="." charoff="50">68.11</td><td align="char" valign="top" char="." charoff="50">68.64</td><td align="char" valign="top" char="." charoff="50">−0.53</td><td align="center" valign="top" charoff="50">−2.77, 1.72</td><td align="center" valign="top" charoff="50">0.6454</td></tr><tr><td align="left" valign="top" charoff="50">Treatment-by-time</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">0.1799</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviations: CI=confidence interval; FKSI-15=Functional Assessment of Cancer Therapy Kidney Symptom Index-15; FKSI-DRS=Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease-Related Symptoms; PRO=patient-reported outcomes; VAS=visual analogue scale.</p></fn><fn id="t2-fn2"><p>Analysis based on repeated measures mixed-effects model with terms for treatment, time, and treatment-by-time, with baseline as covariate and time assumed continuous. Larger values correspond to better health states. Individual FKSI items may be reverse coded, as appropriate.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>Treatment differences in the 15 individual FKSI-15 items</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="2" align="center" valign="top" charoff="50"><bold>Estimated mean</bold></th><th colspan="3" align="center" valign="top" charoff="50"> </th></tr><tr><th align="left" valign="top" charoff="50"><bold>Item</bold></th><th align="center" valign="top" charoff="50"><bold>Axitinib (</bold><italic><bold>n</bold></italic><bold>=361)</bold></th><th align="center" valign="top" charoff="50"><bold>Sorafenib (</bold><italic><bold>n</bold></italic><bold>=362)</bold></th><th align="center" valign="top" charoff="50"><bold>Difference</bold></th><th align="center" valign="top" charoff="50"><bold>95% CI</bold></th><th align="center" valign="top" charoff="50"><italic><bold>P</bold></italic><bold>-value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">1. I have a lack of energy<hr></hr></td><td align="center" valign="top" charoff="50">1.52<hr></hr></td><td align="center" valign="top" charoff="50">1.50<hr></hr></td><td align="center" valign="top" charoff="50">0.03<hr></hr></td><td align="center" valign="top" charoff="50">−0.09, 0.15<hr></hr></td><td align="center" valign="top" charoff="50">0.6627<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">2. I am bothered by side effects of treatment<hr></hr></td><td align="center" valign="top" charoff="50">1.43<hr></hr></td><td align="center" valign="top" charoff="50">1.53<hr></hr></td><td align="center" valign="top" charoff="50">−0.11<hr></hr></td><td align="center" valign="top" charoff="50">−0.25, 0.04<hr></hr></td><td align="center" valign="top" charoff="50">0.1399<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">3. I have pain<hr></hr></td><td align="center" valign="top" charoff="50">1.14<hr></hr></td><td align="center" valign="top" charoff="50">1.19<hr></hr></td><td align="center" valign="top" charoff="50">−0.05<hr></hr></td><td align="center" valign="top" charoff="50">−0.18, 0.08<hr></hr></td><td align="center" valign="top" charoff="50">0.4752<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">4. I am losing weight<hr></hr></td><td align="center" valign="top" charoff="50">0.81<hr></hr></td><td align="center" valign="top" charoff="50">0.83<hr></hr></td><td align="center" valign="top" charoff="50">−0.02<hr></hr></td><td align="center" valign="top" charoff="50">−0.14, 0.10<hr></hr></td><td align="center" valign="top" charoff="50">0.7724<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">5. I have bone pain<hr></hr></td><td align="center" valign="top" charoff="50">0.75<hr></hr></td><td align="center" valign="top" charoff="50">0.72<hr></hr></td><td align="center" valign="top" charoff="50">0.03<hr></hr></td><td align="center" valign="top" charoff="50">−0.10, 0.15<hr></hr></td><td align="center" valign="top" charoff="50">0.6782<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">6. I feel fatigued<hr></hr></td><td align="center" valign="top" charoff="50">1.44<hr></hr></td><td align="center" valign="top" charoff="50">1.43<hr></hr></td><td align="center" valign="top" charoff="50">0.01<hr></hr></td><td align="center" valign="top" charoff="50">−0.11, 0.13<hr></hr></td><td align="center" valign="top" charoff="50">0.9157<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">7. I am able to enjoy life<hr></hr></td><td align="center" valign="top" charoff="50">2.27<hr></hr></td><td align="center" valign="top" charoff="50">2.39<hr></hr></td><td align="center" valign="top" charoff="50">−0.12<hr></hr></td><td align="center" valign="top" charoff="50">−0.25, 0.02<hr></hr></td><td align="center" valign="top" charoff="50">0.0925<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">8. I have been short of breath<hr></hr></td><td align="center" valign="top" charoff="50">0.87<hr></hr></td><td align="center" valign="top" charoff="50">0.88<hr></hr></td><td align="center" valign="top" charoff="50">−0.01<hr></hr></td><td align="center" valign="top" charoff="50">−0.11, 0.10<hr></hr></td><td align="center" valign="top" charoff="50">0.9219<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">9. I worry that my condition will get worse<hr></hr></td><td align="center" valign="top" charoff="50">1.44<hr></hr></td><td align="center" valign="top" charoff="50">1.55<hr></hr></td><td align="center" valign="top" charoff="50">−0.11<hr></hr></td><td align="center" valign="top" charoff="50">−0.24, 0.02<hr></hr></td><td align="center" valign="top" charoff="50">0.0918<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">10. I have a good appetite<hr></hr></td><td align="center" valign="top" charoff="50">2.05<hr></hr></td><td align="center" valign="top" charoff="50">2.09<hr></hr></td><td align="center" valign="top" charoff="50">−0.04<hr></hr></td><td align="center" valign="top" charoff="50">0.18, 0.11<hr></hr></td><td align="center" valign="top" charoff="50">0.6078<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">11. I have been coughing<hr></hr></td><td align="center" valign="top" charoff="50">0.71<hr></hr></td><td align="center" valign="top" charoff="50">0.71<hr></hr></td><td align="center" valign="top" charoff="50">0.00<hr></hr></td><td align="center" valign="top" charoff="50">−0.11, 0.10<hr></hr></td><td align="center" valign="top" charoff="50">0.9354<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">12. I am bothered by fever<hr></hr></td><td align="center" valign="top" charoff="50">0.13<hr></hr></td><td align="center" valign="top" charoff="50">0.15<hr></hr></td><td align="center" valign="top" charoff="50">−0.02<hr></hr></td><td align="center" valign="top" charoff="50">−0.07, 0.04<hr></hr></td><td align="center" valign="top" charoff="50">0.5989<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">13. I am able to work (includes work from home)<hr></hr></td><td align="center" valign="top" charoff="50">1.92<hr></hr></td><td align="center" valign="top" charoff="50">1.92<hr></hr></td><td align="center" valign="top" charoff="50">−0.01<hr></hr></td><td align="center" valign="top" charoff="50">−0.15, 0.14<hr></hr></td><td align="center" valign="top" charoff="50">0.9391<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">14. I have blood in my urine<hr></hr></td><td align="center" valign="top" charoff="50">0.03<hr></hr></td><td align="center" valign="top" charoff="50">0.04<hr></hr></td><td align="center" valign="top" charoff="50">−0.02<hr></hr></td><td align="center" valign="top" charoff="50">−0.04, 0.00<hr></hr></td><td align="center" valign="top" charoff="50">0.1369<hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">15. I am sleeping well</td><td align="center" valign="top" charoff="50">2.36</td><td align="center" valign="top" charoff="50">2.29</td><td align="center" valign="top" charoff="50">0.06</td><td align="center" valign="top" charoff="50">−0.07, 0.19</td><td align="center" valign="top" charoff="50">0.3543</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviations: CI=confidence interval; FKSI-DRS=Functional Assessment of Cancer Therapy–Kidney Cancer Symptom Index-disease-related symptoms subscale; FKSI-15=Functional Assessment of Cancer Therapy Kidney Symptom Index-15.</p></fn><fn id="t3-fn2"><p>Analysis based on repeated measures mixed-effects model with terms for treatment, time, and treatment-by-time, with baseline as covariate and time assumed continuous. Means are based on observed scores 0–4, where 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. A larger score may correspond to a better or worse health state depending on the item question. FKSI-DRS consists of questions 1, 3, 4, 5, 6, 8, 11, 12, and 14 of the FKSI-15.</p></fn></table-wrap-foot></table-wrap></floats-group></article>